Smart Scaffolding Aims to Rebuild Tissue from the Inside Scientists at Rice and the Texas A&M Health Science Center Baylor College of Dentistry received a $1.7 million, five-year grant from the National Institutes of Health (NIH) to develop a hydrogel that can be injected into a patient to form an active biological scaffold. [Rice University ] Press Release NeoStem Receives Notification of $1.2 million NIH Grant Award for First Clinical Study of VSELTM Technology in Humans NeoStem, Inc. announced that it has been awarded a two year grant totaling $1,221,854 for “Repair of Bone Defects with Human Autologous Pluripotent Very Small Embryonic-Like Stem Cells (VSEL)”, grant number 2R44DE022493-02A1, from the National Institute of Dental and Craniofacial Research, a division of the National Institutes of Health (NIH). [NeoStem, Inc.] Press Release Cardio3 BioSciences Receives Authorization to Begin World’s First Phase III Clinical Trial in Regenerative Medicine for Heart Failure The Belgian biotechnology company, Cardio3 BioSciences (C3BS), announced that it has received authorization from the Belgian Federal Agency for Medicines and Health Products to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy European Phase III trial for C3BS-CQR-1 in Belgium. This represents a world premiere for a regenerative medicine product targeting heart failure to be tested in the context of a Phase III trial. C3BS-CQR-1 is an autologous stem cell therapy for heart failure. [Cardio3 Biosciences] Press Release LCT Starts DIABECELL® Phase IIb Trial in Argentina Living Cell Technologies (LCT) Limited has begun patient recruitment in Argentina for a Phase IIb trial of DIABECELL. The trial is designed to demonstrate the clinical benefits of DIABECELL in unstable type 1 diabetes. Twenty patients will receive two implants of 10,000 IEQ/kg (islet equivalents per kilogram of body weight), with the second implant occurring 12 weeks after the first. [Living Cell Technologies Limited] Press Release Mesoblast Reaches Key Manufacturing Agreement with FDA for Supply of Mesenchymal Precursor Cells in Phase III Clinical Trials Mesoblast Limited announced that it has reached agreement with the United States Food and Drug Administration (FDA) on the manufacturing process to supply its proprietary mesenchymal precursor cells for Phase III clinical trials. In addition, it has established with the FDA a clear pathway for commercial manufacturing supply of its cell therapy products. [Mesoblast Limited] Press Release Bio-Matrix Scientific Group Inc.’s Regen BioPharma Initiates Pre-Clinical Study in Support of HemaXellerate™ Cell Therapy Bio-Matrix Scientific Group, Inc. announced that its wholly owned subsidiary, Regen BioPharma, Inc., has contracted Cascade Life Sciences, Inc. to research the safety and efficacy of Regen’s HemaXellerate™ product using mice models for testing. [Marketwire, Inc.] Press Release
UC-Davis and StemCyte Announce Cord Blood Banking Partnership StemCyte, Inc. announced an agreement with the UC Davis Umbilical Cord Blood Collection Program in Sacramento to advance the collection, processing and registration of high quality and diverse cord blood cells from California mothers for public banking. [StemCyte, Inc.] Press Release
AGTC Secures $37.5M Series B Funding Applied Genetic Technologies Corporation (AGTC) a privately-held, clinical stage biotechnology company developing gene therapy products to treat rare retinal diseases, announced that it has secured $37.5 million in a Series B round of financing. [Applied Genetic Technologies Corporation] Press Release Stem Cell Pioneer Recognized for 20 Years of Discovery and Innovation Dr. David Harris, Professor of Immunology at the University of Arizona and a scientific pioneer in the field of stem cell banking, was the recipient of the Arizona BioIndustry Association™ 2012 award for “20 Years of Discovery and Innovation”. [PR Newswire Association LLC] Press Release |